FH
Fumarate hydratase, mitochondrial
Protein Summary
Also acts as a tumor suppressor. The protein encoded by this gene is an enzymatic component of the tricarboxylic acid (TCA) cycle, or Krebs cycle, and catalyzes the formation of L-malate from fumarate. It exists in both a cytosolic form and an N-terminal extended form, differing only in the translation start site used. The N-terminal extended form is targeted to the mitochondrion, where the removal of the extension generates the same form as in the cytoplasm. It is similar to some thermostable class II fumarases and functions as a homotetramer. Mutations in this gene can cause fumarase deficiency and lead to progressive encephalopathy. [provided by RefSeq, Jul 2008]
- ENST00000366560
- ENSP00000355518
- ENSG00000091483
- MCL
- FMRD
- LRCC
- HLRCC
- MCUL1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
disease perturbation | 0.96 | ||
kinase perturbation | 0.95 | ||
protein domain | 0.92 | ||
co-expressed gene | 0.72 | ||
biological term | 0.71 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 218.56 (req: < 5)
Gene RIFs: 115 (req: <= 3)
Antibodies: 572 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 218.56 (req: >= 5)
Gene RIFs: 115 (req: > 3)
Antibodies: 572 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 6
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0